Previous 10 | Next 10 |
Shares of U.S. vaccine maker Novavax ( NASDAQ: NVAX ) on Tuesday closed about 6% higher , ending an eight-session losing streak which included a ~27% drop in the last three days. On Monday, the stock ended 13.3% in the red , after JPMorgan downgraded the ...
Shares of Novavax (NASDAQ: NVAX) were bouncing back on Tuesday, rising 7.1% as of 12:50 p.m. ET after jumping as much as 14.7% earlier in the day. The gain came after an analyst's downgrade caused the stock to plunge last week . Novavax had good news to report on Tuesday, th...
Novavax ( NASDAQ: NVAX ) on Tuesday said an initial 1M doses of its COVID-19 vaccine was now available for use in the United Kingdom. UK's health regulator granted a conditional marketing approval to the protein-based shot, called Nuvaxovid, for use in adults in Feb. and i...
Novavax Makes One Million Doses of Nuvaxovid™ Available for Use in the United Kingdom PR Newswire GAITHERSBURG, Md. , Sept. 27, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips As people acclimatize to the new normal, it’s time to look at some vaccine stocks to sell. Instead of relying primarily on vaccines and antiviral drugs, the government let people manage infections. Once infected wi...
In the early days of the pandemic, if there was one coronavirus vaccine stock investors were betting on, it was Novavax (NASDAQ: NVAX) . The biotech stock soared more than 2,700% in 2020 as it developed its vaccine candidate. That beat the early performance of today's vaccine leader...
The Novavax (NASDAQ: NVAX) rollercoaster has been a wild one. The stock soared more than 2,700% in 2020 after the company received $1.6 billion from the U.S. government to develop the COVID-19 vaccine we now know as Nuvaxovid. Unfortunately, Novavax didn't receive authorization ...
Shares of Novavax (NASDAQ: NVAX) were plunging 26.3% this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence . Two factors contributed to the dismal performance. First, the overall stock market tumbled as investors ...
Analyst commentary provided a key catalyst during Thursday's midday trading. This included Novavax ( NASDAQ: NVAX ), which dropped as JPMorgan turned bearish on the COVID vaccine maker. Luminar Technologies ( LAZR ) also plummeted on an analyst downgrade. Meanwhile, Tesla ( ...
Shares of the recombinant-protein vaccine specialist Novavax (NASDAQ: NVAX) were down by a noteworthy 9.2% on heavy volume as of 9:55 a.m. ET on Thursday. As a result, the biotech's stock price hit a fresh 52-week low this morning. What's weighing on Novavax's shares today? ...
News, Short Squeeze, Breakout and More Instantly...
Believes the two new nominated directors possess the necessary experience to tackle the underperformance of the business which will improve its sh...
Believes the two new nominated directors possess the necessary experience to tackle the underperformance of the business which will improve its share price Shah Capital which owns 6.7% of Novavax, in a letter to the board says that the low share price reflects the board and management...
2024-04-13 16:22:00 ET If there is one thing Bluebird Bio (NASDAQ: BLUE) and Novavax (NASDAQ: NVAX) have in common, other than their belonging to the biotech industry, it is that both have seen their shares drop catastrophically in recent years. Bluebird's stock is down by 9...